Verve Therapeutics Inc (NASDAQ:VERV) has a beta value of 1.68 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $432.94M, closed the last trade at $4.85 per share which meant it gained $0.25 on the day or 5.43% during that session. The VERV stock price is -298.76% off its 52-week high price of $19.34 and 11.34% above the 52-week low of $4.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.08 million shares traded. The 3-month trading volume is 1.40 million shares.

The consensus among analysts is that Verve Therapeutics Inc (VERV) is Buy stock at the moment, with a recommendation rating of 1.36. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.

Verve Therapeutics Inc (NASDAQ:VERV) trade information

Sporting 5.43% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the VERV stock price touched $4.85 or saw a rise of 1.62%. Year-to-date, Verve Therapeutics Inc shares have moved -65.21%, while the 5-day performance has seen it change 1.25%. Over the past 30 days, the shares of Verve Therapeutics Inc (NASDAQ:VERV) have changed -15.21%. Short interest in the company has seen 17.23 million shares shorted with days to cover at 16.17.

Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 65.36% from current levels. The projected low price target is $13.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -518.56% off the targeted high while a plunge would see the stock gain -168.04% from current levels.

Verve Therapeutics Inc (VERV) estimates and forecasts

Figures show that Verve Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -8.14% over the past 6 months, with this year growth rate of 20.19%, compared to 16.70% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -67.06% over the past 5 years.

VERV Dividends

Verve Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders

Insiders own 1.78% of the company shares, while shares held by institutions stand at 97.75% with a share float percentage of 99.52%. Investors are also buoyed by the number of investors in a company, with Verve Therapeutics Inc having a total of 256.0 institutions that hold shares in the company. The top two institutional holders are ALPHABET INC. with over 12.35 million shares worth more than $60.26 million. As of 2024-06-30, ALPHABET INC. held 14.8546% of shares outstanding.

The other major institutional holder is BLACKROCK INC., with the holding of over 6.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $32.31 million and represent 7.9632% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.81% shares in the company for having 2.37 shares of worth $11.52 million while later fund manager owns 2.15 shares of worth $10.45 million as of Jun 30, 2024 , which makes it owner of about 2.54% of company’s outstanding stock.